Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2470

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2470
---
 intended
    to allow us to provide attractive economic incentives to the institution and its relevant investigators. We intend in the future,
    as new programs are licensed in by us, to grant a certain percentage of the ownership in the new subsidiaries we create for such
    programs, targeting 20% in aggregate, to the institution and to the researchers. This model is also designed to align our interests
    with those of our partners and to facilitate our access to the particular program’s scientific expertise and know-how. We believe
    this approach will make us the partner of choice or licensee of choice for institutions and researchers because we aim to act with
    greater speed and to provide better potential upside when compared to pharmaceutical companies or venture-backed biotechnology companies
    with whom the institution might also consider partnering.

    ●
    We
    believe that our diversified pipeline approach provides us with meaningful advantages: Unlike biotechnology companies that are focused
    on a narrow set of assets, on a single platform, or on a particular therapeutic area, we are advancing a diverse portfolio of several
    programs in parallel. In so doing, we aim to avoid the duplication of resources, the extra costs and the lack of valuable cross-pollination
    that would likely exist if each program were pursued as independent assets. We are evidence-based and program agnostic, where deployment
    of program resources are driven strictly by program progress and milestone achievements. We believe that our diverse, multi-program
    business model and our access to a robust pipeline of opportunities helps us to remain focused on the most promising assets. We believe
    this focus differentiates us advantageously from biotech companies that, by purposely being focused, have bet their fortunes on a
    limited number of programs.

    ●
    We
    aim to create optionality for maximum impact and value creation in each program: Throughout the development of any program we continuously
    assess that program’s potential paths to market and monetization. We anticipate that such paths may include: (a) taking a candidate
    all the way through to potential approval and product launch via internal funding; (b) externalizing development with a strategic
    partner that we believe is better suited to progress a program; and (c) spinning out or taking a candidate’s subsidiary public.
    We believe that our structure and operational strategy enables us to objectively assess and choose the option that maximizes potential
    value for patients and for our shareholders.

Our
Structure: Supporting Innovation

We
are structured in a manner